• Guide marketing strategies and engage with potential partners across various therapeutic approaches, including Adimab's technology related to monoclonal and multispecific antibody discovery and optimization, T-cell engagers, TCRs, GPCRs and other membrane-obligate targets, as well as other existing and new technology offerings.• Help lead internal cross-functional efforts to develop competitive intelligence, perform internal and external technology analysis, and drive external technical engagement with drug development companies, key opinion leaders, and industry leaders.

Leads virtual company focused on novel serine proteinase inhibitors discovery, engineering, and development to treat rare diseases such as alpha-1-antitrypsin (AAT) deficiency. Lead development candidate is an engineered long-acting AAT albumin fusion, resistant to lung oxidation and loop-sheet polymerization.Impact: Discovered 1) protein-based kunitz domain human neutrophil elastase inhibitor; 2) engineered AAT albumin fusion to treat AAT deficiency.

Provides the pharma and biotechnology industry with an end-to-end antibody discovery and optimization solution utilizing our proprietary DNA writing technology, proprietary mouse platform, and cutting-edge machine learning/AI technologies.Senior management team member. Oversees Twist Biopharma Solutions revenue-generating business to discover/develop novel antibody therapeutics for Twist’s strategic partners. Routinely presents to Board of Directors on commercial targets and forecasts for Twist Biopharma Solutions business unit. Team discovers/optimizes antibodies from synthetic libraries, animal immunizations (mice, alpacas), and machine learning/AI technologies. Impact: • Led Biopharma 70+ member team formation from ground-up. Developed new high performing leaders.• Generated $20M+ revenue/year for the business.

Drives new custom Biopharma-inspired product creation that stem from Twist’s DNA synthesis platform, e.g. HT lgG and combinatorial assembly librariesLeads new Biopharma division product initiatives, Biopharma pipeline efforts to create new internal preclinical leads for out-licensing and spin-out efforts (interim scientific leader of new Twist spin-outs such as Revelar). M&A team member and executive sponsor for new drug discovery and CRO acquisitions such as Abveris. Presents DNA products and services at scientific conferences on behalf of the company. Concurrent with General Manager, Twist Biopharma Solutions.

Provides biotechnology industry with end-to-end antibody discovery solution using proprietary DNA writing technology to create oligo pools, genes, and synthetic libraries.Senior management team member; routinely presents to Board of Directors on strategic plans. Oversees Twist Biopharma revenue-generating vertical to discover/develop novel antibody therapeutics for Twist and strategic partners. Team discovers/optimizes antibodies from synthetic libraries and machine learning/AI. Impact: • Led Biopharma 50+ member team formation from ground-up. Developed new high performing leaders.• Generated $10M+ revenue/year for business.• Discovered: 1) panel of antibody leads against array of targets; completed first lead option deal in 2022; 2) first-in-class anti-GPCR antibody antagonists against GLP1R and ADORA2A; best-in-class anti-SARS-CoV-2 therapeutics (anti-Spike S1, anti-ACE2) to treat COVID-19; best-in-class anti-DKK1 to treat gastric/gastroesophageal junction cancer.

Global biologics provider for protein engineering, antibody drug development, biomanufacturing, integrated solutions. (Now part of Curia.)Oversaw the California Antibody Center (50 scientists, 15 PhDs) to discover novel antibody therapeutics using animal immunization (mice/rats) and library-based (phage, yeast display) approaches. Partnered with outside sales team to recruit new clients/projects. Led LakePharma Antibody Technology Network to establish relationships with third party antibody-based technologies and expand technology capabilities to clients. Presented at scientific conferences on behalf of LakePharma.Impact:• Generated $50M+ revenue/year for core business.• Improved CRO services to partners by elevating staff scientific expertise.• Helped start-up and small companies discover/generate their own biologics to treat patients.

Directed discovery research functions for biopharmaceutical startup founded by Stanford University scientists, Drs. Chris Garcia, Roel Nusse, and Calvin Kuo. Harnessed key signaling pathways to identify regenerative medicine novel therapeutics; leveraged the founders’ breakthrough insights in protein engineering, stem cell dynamics, and developmental biology. Impact: • Hired the team that discovered key antibody leads and established foundational IP for company formation.• Set up the antibody platform that found anti-LRP5/6 and anti-Fzd antibodies to create novel Wnt-mimetic bispecifics.• Established company’s core IP technology.

Senior leadership team member, JSC member for major partner collaborations (Celgene immune-oncology bispecifics, Merck Serono ADCs); project team leader for internal technology development and novel immune-oncology bispecifics, and client initiatives. Presented technology at conferences and to Board of Directors on research.Directed antibody/protein engineering, protein biochemistry, informatics, and chemistry research functions. Led 30 scientists (18 PhDs) to discover bispecific antibodies and antibody drug conjugates; used Sutro’s novel Xpress CF (natural antibodies) and CF+ (non-natural amino acid antibodies) platforms to produce:• Anti-tumor antigen antibodies (receptor agonists/antagonists)• Bispecific T-cell engagers (Immuno-oncology, recruit T-cells to tumor)• Dual checkpoint antagonist bispecifics (Immuno-oncology, e.g. block both PD1/CTLA4)• Antibody drug conjugates (ADCs) to over-expressed tumor antigens• VaccinesImpact: • Discovered: 1) antibody drug conjugates for array of tumor targets including Folate Receptor Alpha and CD74 (Invariant Chain); 2) hemiasterlin-based novel toxins for paring with Sutro’s site-specific ADCs platform.• Created: 1) novel immune-oncology monospecific (such as CD47) and bispecific antibodies (such as PD1/LAG3 for Celgene/BMS); 2) novel bispecific ADCs for Merck against EGFR and MUC-1.

Led antibody lead discovery and antibody engineering, focused on cancer stem cell targets. Project team leader for preclinical antibody leads. Managed internal research and process development and timeline development/tracking. Coordinated IND-enabling studies with contract research organizations. Prepared summaries and presentations for board meetings. Coordinated FDA pre-IND filings.Projects: 1) Target expression and purification (Baculovirus and Mammalian); 2) Naïve human antibody library generation (phage and mammalian display); 3) Murine hybridoma and high throughput screening; 4) Antibody phage selections; 5) Lead affinity maturation; 6) Fab expression and purification; 7) Antibody reformatting; 8) Transient and stable cell line development (HEK293 and CHO); 9) Lead engineering: humanization, bispecific, Fc engineering. 10) Cell based assay developmentImpact:• Discovered: several antibodies that entered clinical development (anti-Notch2/3, anti-Fzd1/2/5/7/8, anti-VEGF/DLL4 bispecific). Team leader for all studies that led to IND.• Created: several antibody discovery platforms in phage and mammalian display.

Led antibody, peptide, and small protein discovery through proprietary phage display technology. Sr. Director, Lead Discovery: Oversaw funded or co-development collaborations with major pharmaceutical (Pfizer), imaging (Bracco, EPIX Pharmaceuticals), and biotechnology partners (Biogen Idec, Amgen, Inhibitex, Syntonix, Tanox, Genzyme, Human Genome Sciences).Directed Cambridge site lead discovery groups; 17+ Scientists (6 PhDs).Selection/Screening Group: Used antibody/peptide/protein phage display libraries to find therapeutic leads for both internal and external projects; HT automated screening.Molecular Biology Group: Maintained phage library; directed library technology transfers, sequencing, lead cloning, and bioinformatics.Impact: Reorganized team for greater efficiency; hired key staff members. Managed external collaborations (Bracco and Biogen) that resulted in leads for development.Director, Molecular Biology: Directed 7+ member team of scientists; collaborated with clients to find peptides, proteins, and human antibodies against targets for therapeutic and/or diagnostic use to treat blood disorders, cancer, and inflammation.Associate Director, Molecular Biology: Directed 5+ member team of scientists to discover/produce peptide and antibody-based imaging agents for cancer, blood disorders, and heart disease applications; used Dyax phage display libraries in collaboration with Bracco Research USA – diagnostic imaging company.Senior Scientist: Supervised screening of protein targets against Dyax phage display libraries (antibody and peptide); used isolated binders for downstream applications (imaging agents, affinity chromatography, therapeutics).